1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with naproxen in 5 studies
| Studies (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Trials (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Recent Studies (post-2010) (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Studies (naproxen) | Trials (naproxen) | Recent Studies (post-2010) (naproxen) |
|---|---|---|---|---|---|
| 9,156 | 187 | 552 | 4,551 | 1,057 | 1,429 |
| Protein | Taxonomy | 1-hexadecyl-2-acetyl-glycero-3-phosphocholine (IC50) | naproxen (IC50) |
|---|---|---|---|
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | 1.1642 | |
| Hormone-sensitive lipase | Rattus norvegicus (Norway rat) | 1.2 | |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 4.0203 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 3.8725 | |
| Prostaglandin G/H synthase 2 | Rattus norvegicus (Norway rat) | 0.06 | |
| Aldo-keto reductase family 1 member C3 | Homo sapiens (human) | 0.5867 | |
| Aldo-keto reductase family 1 member C2 | Homo sapiens (human) | 1.26 | |
| Prostaglandin G/H synthase 2 | Ovis aries (sheep) | 3.36 | |
| Solute carrier family 22 member 6 | Homo sapiens (human) | 5.8 | |
| Prostaglandin G/H synthase 1 | Rattus norvegicus (Norway rat) | 0.06 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (40.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ferrell, JB; Fleisher, LN; McGahan, MC; Smith, MG | 1 |
| Audette, CA; Burstein, SH; Doyle, SA; Hull, K; Hunter, SA; Latham, V | 1 |
| Clark, JS; Jubb, SN; Maloney, PJ; Young, JM | 1 |
| Mue, S; Ohuchi, K; Watanabe, M; Yamada, M | 1 |
| Downing, SJ; Leese, HJ; Maguiness, SD; Tay, JI; Watson, A | 1 |
5 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and naproxen
| Article | Year |
|---|---|
Lipid mediators of tumor necrosis factor-alpha-induced uveitis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aqueous Humor; Eicosanoids; Eye Proteins; Indomethacin; Leukocyte Count; Leukotriene B4; Male; Naproxen; Platelet Activating Factor; Prostaglandins E; Quinolinium Compounds; Rabbits; Recombinant Proteins; Tumor Necrosis Factor-alpha; Uveitis, Anterior; Vitreous Body | 1991 |
Antagonism to the actions of platelet activating factor by a nonpsychoactive cannabinoid.
Topics: Animals; Arachidonic Acid; Arachidonic Acids; Cannabinoids; Dronabinol; Edema; Female; Hydroxyeicosatetraenoic Acids; Mice; Naproxen; Platelet Activating Factor; Structure-Activity Relationship | 1989 |
Pharmacological investigation of the mechanisms of platelet-activating factor induced mortality in the mouse.
Topics: Anaphylaxis; Animals; Chloroquine; Chlortetracycline; Dexamethasone; Dose-Response Relationship, Drug; Female; Indomethacin; Injections, Intravenous; Male; Mice; Mice, Inbred DBA; Naproxen; Nicardipine; Nifedipine; Platelet Activating Factor; Pyrazoles; Quinacrine; Tetracycline; Verapamil | 1985 |
Enhancement by cyclo-oxygenase inhibitors of platelet-activating factor production in thapsigargin-stimulated macrophages.
Topics: Animals; Arachidonic Acid; Bucladesine; Cyclooxygenase Inhibitors; Dinoprostone; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; Ibuprofen; Indomethacin; Macrophages, Peritoneal; Male; Naproxen; Platelet Activating Factor; Radioimmunoassay; Rats; Rats, Sprague-Dawley; Terpenes; Thapsigargin | 1995 |
Effect of inflammatory mediators on the physiology of the human Fallopian tube.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cells, Cultured; Diclofenac; Dose-Response Relationship, Drug; Electric Conductivity; Electrophysiology; Epithelial Cells; Fallopian Tubes; Female; Histamine; Humans; Ibuprofen; Indomethacin; Inflammation Mediators; Muscle Contraction; Muscle, Smooth; Naproxen; Pelvic Pain; Platelet Activating Factor | 2002 |